



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/668,661	09/23/2003	Jean-Claude Yvin	16721-0250 (42528-292745)	1057
881 7590 08/24/2007 STITES & HARBISON PLLC 1199 NORTH FAIRFAX STREET SUITE 900 ALEXANDRIA, VA 22314			EXAMINER HENRY, MICHAEL C	
			ART UNIT 1623	PAPER NUMBER
			MAIL DATE 08/24/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**Office Action Summary**

Application No.

10/668,661

Applicant(s)

YVIN ET AL.

Examiner

Michael C. Henry

Art Unit

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11 April 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 23-34 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 23-34 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### DETAILED ACTION

The following office action is a responsive to the amendment filed, 04/11/07.

The amendment filed 04/11/07 affects the application, 10/668,661 as follows:

Applicant's arguments and Declaration under 37 CFR 1.132 filed 04/11/07 is sufficient to overcome the rejection as applied under 35 U.S.C. 103 as set forth in the prior office action mailed 12/11/06. The responsive to applicants' arguments is contained herein below.

Claims 23-34 are pending in the application

#### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 23-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsuzuki et al. (Bioscience, Biotechnology, and Biochemistry, (1999 Jan) Vol. 63, No. 1, pages 104-110) in view of Fan et al. (Zhongguo Yaoke Daxue Xuebao (1988), 19 (1), pages 30-34) (Abstract Only).

In claim 23, applicant claims a method of promoting the regeneration of the cells in the bone marrow and the peripheral blood of a patient, said patient being subjected to a chemotherapeutic antineoplastic treatment comprising administration to said patient of an effective amount of an antineoplastic agent which causes an acute reduction of the said cells due to the effect of the antineoplastic agent, said method comprising administering laminarin to the

Art Unit: 1623

patient in an amount effective to cause promotion of the regeneration of the cells, said laminarin being administered in conjunction with the administration of the antineoplastic agent. Claim 24 is drawn the method of claim 23, wherein the antineoplastic agent is cyclophosphamide. Claims 25 and 26 are drawn to said method wherein laminarin is administered by specific routes. Claims 27 and 28 are drawn to said method wherein laminarin is administered before, simultaneously with or after the antineoplastic agent or the cyclophosphamide. Claims 17-22 are drawn to said method wherein laminarin is soluble laminarin.

Tsuzuki et al. disclose a method of promoting the formation (regeneration) of blood marrow cells (hematopoiesis) of a patient (mice), said patient being subjected to a chemotherapeutic antineoplastic treatment comprising administration to said patient of an effective amount of an antineoplastic agent (cyclophosphamide) which causes an acute reduction of the said cells (leukopenia) due to the effect of the antineoplastic agent (cyclophosphamide), said method comprising administering a soluble glucan to the patient in an amount effective to cause the promotion of the formation (regeneration) of blood cells, said glucan being administered in conjunction with the administration of the antineoplastic agent (cyclophosphamide) (see abstract). Furthermore, Tsuzuki et al. disclose that the said glucan increase hematopoietic responses or exhibits hematopoietic activity (i.e. they promote the formation (regeneration) of blood cells) (see abstract). In addition, Tsuzuki et al. suggest that the conformation of the glucans are independent of the hematopoietic response caused by the glucans (see abstract).

The difference between applicant's claimed method and Tsuzuki et al.'s method is that Tsuzuki et al. do not use the specific glucan, laminarin.

Art Unit: 1623

Fan et al. disclose that the glucan, laminarin, exhibits remarkable antagonistic action to leukopenia and remarkable antiradiation effect (see abstract). This implies that the glucan, laminarin oppose, prevent or act against an acute reduction of the said cells (leukopenia).

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made, in view of Tsuzuki et al. and Fan et al., to have used the method of Tsuzuki et al. to promote the regeneration of the cells in the bone marrow and the peripheral blood of a patient who is being subjected to a chemotherapeutic antineoplastic treatment of a antineoplastic agent such as cyclophosphamide that causes the said reduction, by administering the glucan, laminarin since Tsuzuki et al. disclose that glucans (which includes laminarin) promote the formation (regeneration) of blood cells and Fan et al. teach that the glucan, laminarin, also opposes, prevent or act against an acute reduction of the said cells (leukopenia).

One having ordinary skill in the art would have been motivated in view of Tsuzuki et al. and Fan et al., to have used the method of Tsuzuki et al. to promote the regeneration of the cells in the bone marrow and the peripheral blood of a patient who is being subjected to a chemotherapeutic antineoplastic treatment of a antineoplastic agent such as cyclophosphamide that causes the said reduction, by administering the glucan, laminarin, based on factors such as the type, and/or severity of the leukopenia caused by said treatment, and since Tsuzuki et al. disclose that glucans (which includes laminarin) promote the formation (regeneration) of blood cells and Fan et al. teach that the glucan, laminarin, also opposes, prevent or act against an acute reduction of the said cells (leukopenia). It should be noted that the use of specific routes and ways of administration of said composition is common and obvious in the art, and is well within the purview of a skilled artisan.

Art Unit: 1623

***Response to Amendment***


Applicant's arguments with respect to claims 23-34 have been considered but are moot in view of the new ground(s) of rejection.

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8.30am-5pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael C. Henry

  
Shaojia Anna Jiang, Ph.D.  
Supervisory Patent Examiner  
Art Unit 1623

August 17, 2007.